DAHs may be considered as an alternative option to other conventional grafts for AVR and EARR, particularly for young patients with contraindications for warfarin and patients with impaired left ventricular function, as EOAs are outstanding. In infants, DAH implantation might require a more complex reconstruction of the LVOT to avoid subvalvular stenosis, especially in patients with very small aortic rings. Further prospective clinical controlled trials will be needed to confirm these encouraging early results and have been initiated by us within the HORIZON 2020 programme of the European Union.